Nektar Therapeutics
NASDAQ:NKTR

  • LAST PRICE
    1.0500
  • TODAY'S CHANGE (%)
    0.0400 (3.9604%)
  • Bid / Lots
    1.0500/ 1
  • Ask / Lots
    1.1000/ 5
  • Open / Previous Close
    1.0300 / 1.0100
  • Day Range
    1.0100
    1.1100
  • 52 Week Range
    0.4227
    1.9280
  • Volume
    4,632,234

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 18, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:27PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: NKTR
      04:27 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:15PM ET on Thursday Nov 07, 2024 by PR Newswire
      Companies Mentioned: NKTR

      Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024.

      https://mma.prnewswire.com/media/1390052/nektar_logo.jpg

      Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026.

    • 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: NKTR
      revenue 378 155 534 179 Total revenue 24,124 24,144 69,252 66,237 ------------------------------ ----------------------------- ----------------------------- ----------------------------- Operating costs and expenses: Cost of goods sold 4,435 12,431 22,709 26,485 Research and development 35,031 24,070 92,163 84,220 General and administrative 18,957 21,147 59,616 60,097 Restructuring, impairment and costs of terminated program 46 11,360 14,310 49,107 Impairment of goodwill - - - 76,501 Total operating costs and expenses 58,469 69,008 188,798 296,410 ------------------------------ ----------------------------- ----------------------------- ----------------------------- Loss from operations (34,345) (44,864) (119,546) (230,173) ------------------------------ ----------------------------- ----------------------------- ----------------------------- Non-operating income (expense): Non-cash interest expense on liabilities related to the sales of future royalties (6,020) (5,910) (17,959) (18,467) Interest income 3,437 5,211 11,558 14,392 Other income (expense), net (120) (335) (255) 100 Total non-operating income (expense), net (2,703) (1,034) (6,656) (3,975) ------------------------------ ----------------------------- ----------------------------- ----------------------------- Loss before provision for income taxes (37,048) (45,898) (126,202) (234,148) Provision (benefit) for income taxes 9 (61) 20 (171) Net loss $ (37,057) $ (45,837) $ (126,222) $ (233,977) ============================== ============================= ============================= ============================= Basic and diluted net loss per share $ (0.18) $ (0.24) $ (0.62) $ (1.23) ============================== ============================= ============================= ============================= Weighted average shares outstanding used in computing basic and diluted net loss per share 209,249 190,406 204,292 189,651 ============================== ============================= ============================= =============================

    • 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: NKTR
      revenue 378 155 534 179 Total revenue 24,124 24,144 69,252 66,237 ------------------------------ ----------------------------- ----------------------------- ----------------------------- Operating costs and expenses: Cost of goods sold 4,435 12,431 22,709 26,485 Research and development 35,031 24,070 92,163 84,220 General and administrative 18,957 21,147 59,616 60,097 Restructuring, impairment and costs of terminated program 46 11,360 14,310 49,107 Impairment of goodwill - - - 76,501 Total operating costs and expenses 58,469 69,008 188,798 296,410 ------------------------------ ----------------------------- ----------------------------- ----------------------------- Loss from operations (34,345) (44,864) (119,546) (230,173) ------------------------------ ----------------------------- ----------------------------- ----------------------------- Non-operating income (expense): Non-cash interest expense on liabilities related to the sales of future royalties (6,020) (5,910) (17,959) (18,467) Interest income 3,437 5,211 11,558 14,392 Other income (expense), net (120) (335) (255) 100 Total non-operating income (expense), net (2,703) (1,034) (6,656) (3,975) ------------------------------ ----------------------------- ----------------------------- ----------------------------- Loss before provision for income taxes (37,048) (45,898) (126,202) (234,148) Provision (benefit) for income taxes 9 (61) 20 (171) Net loss $ (37,057) $ (45,837) $ (126,222) $ (233,977) ============================== ============================= ============================= ============================= Basic and diluted net loss per share $ (0.18) $ (0.24) $ (0.62) $ (1.23) ============================== ============================= ============================= ============================= Weighted average shares outstanding used in computing basic and diluted net loss per share 209,249 190,406 204,292 189,651 ============================== ============================= ============================= =============================

Peers Headlines